![Rashed Dewan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 572 691 $ al 30/06/2026
Rashed Dewan is currently Chief Financial Officer at Profound Medical Corp.
since 2022.
Formerly, Mr. Dewan worked as Controller at Profound Medical, Inc. Mr. Dewan completed undergraduate studies at the University of Southern California.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PROFOUND MEDICAL CORP 0,24 % | 24/06/2026 | 86.119 ( 0,24 % ) | 572 691 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PROFOUND MEDICAL CORP. | Director Financiero/CFO | 03/03/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
Profound Medical, Inc.
 Profound Medical, Inc. Medical SpecialtiesHealth Technology Develops and commercializes a unique, minimally invasive treatment for prostate cancer | Comptroller/Controller/Auditor | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Profound Medical, Inc.
Profound Medical, Inc. Medical SpecialtiesHealth Technology Develops and commercializes a unique, minimally invasive treatment for prostate cancer | Health Technology |
Profound Medical Corp.
 Profound Medical Corp. Medical SpecialtiesHealth Technology Develops and markets medical devices focused on prostate cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
